AGP Executive Report
Last update: 4 hours agoBiotech & Health: The European Commission has authorized CinnaGen’s teriparatide biosimilar Zandoriah® for adult osteoporosis, giving an EU-wide platform that also covers Liechtenstein and Norway (with local conditions still applying). Life-Saving Medicines: SERB Pharmaceuticals says it has completed its acquisition of Idefirix® (imlifidase) rights across the EU, UK, Switzerland, Norway, Liechtenstein and MENA, aiming to expand access for rare, time-critical transplant use. Rett Syndrome Breakthrough: Neuren’s partner Acadia won a positive EMA CHMP opinion for Daybu (trofinetide) in the EU for neurobehavioral symptoms of Rett syndrome, moving the decision to the European Commission. Finance & Banking Tech: Objectway agreed to buy FNZ’s Swiss private banking technology business (formerly New Access), boosting its core-to-digital platform and strengthening its presence in Switzerland and Liechtenstein. Trade & Policy: EFTA and Vietnam concluded a long-running free trade agreement, expected to cut barriers and improve market access for services, investment, IP and procurement—relevant for Liechtenstein as part of EFTA. Digital Assets in Europe: Sygnum Europe is scaling its EU reach under a Liechtenstein CASP licence as MiCAR transitions settle.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
